Sunildat Maheshwari, MD
Family Medicine · Gilbert, AZNPI 1417153164
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (58.6%), food and beverage and education — rather than concentrated in one kind of arrangement. Eli Lilly accounts for 62.3% of it on its own, with 56 other manufacturers making up the rest. Reporting peaked in 2023 at $14,955 and has fallen 86.5% since, to $2,024 in 2025. Among family medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 578 payments — averaging $41.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$15K
- AbbVie$1K
- AstraZeneca$999
- Novo Nordisk$832
- Lilly USA, LLC$564
- Pfizer$514
- plus $5K from 51 others
Across 123 payments — averaging $16,798 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.2M
- Amgen$492K
- AstraZeneca$255K
- GSK$37K
- Alnylam Pharmaceuticals Inc.$27K
- Teva Pharmaceuticals USA, Inc.$14K
What the payments were for
- Travel & lodging$13,92559%
- Food & beverage$9,72441%
- Education$780%
- Entertainment$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,748 in reported general payments places this provider in the 95th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $106,113 |
| MounjaroTirzepatide | 71 | $78,070 |
| JardianceEmpagliflozin | 33 | $53,432 |
| EliquisApixaban | 38 | $47,354 |
| XareltoRivaroxaban | 36 | $44,352 |
| RybelsusSemaglutide | 16 | $38,944 |
| TrulicityDulaglutide | 18 | $28,195 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $27,246 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $23,852 |
| FarxigaDapagliflozin Propanediol | 15 | $21,759 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $15,854 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $10,487 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $9,448 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $8,892 |
| PaxlovidNirmatrelvir/Ritonavir | 31 | $7,145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $832 | $145,05792 claims |
| Lilly USA, LLCMounjaro, Trulicity | $564 | $106,26589 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $329 | $80,67846 claims |
| PfizerEliquis, Paxlovid | $514 | $54,49969 claims |
| Johnson & JohnsonXarelto | $165 | $44,35236 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $999 | $37,61339 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $414 | $33,30047 claims |
| AbbVieSynthroid | $1,407 | $1,48930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Gilbert
- David BentonGilbert$18K
- Zachary OrtizGilbert$13K
- Steven ReederGilbert$13K
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Lorena Jauregui-CovarrubiasYuma$491K
- Sam FereidouniScottsdale$486K
- Jessica BlancoChandler$447K
- Heather ElwoodPhoenix$236K
- Ryan CaseyYuma$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.